RE: RNS - Dr. Reddy's!8 Jun 2020 11:30
Business summary
Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients and intermediates (API) or bulk drugs. Proprietary Products segment focuses on the research, development and manufacture of differentiated formulations and new chemical entities. These products fall within the dermatology and neurology therapeutic areas, and are marketed and sold through its subsidiary, Promius Pharma, LLC.
Contact details
Address:
8-2-337, Road No.3 Banjara Hills
HYDERABAD
500-034
India
Telephone:
+91 (40) 49002900
Website:
www.drreddys.com/
General stock information
Short code:
RDY
ISIN:
US2561352038
Market cap:
$8.84 billion
Shares in issue:
165.78 million
Sector:
Pharmaceuticals
Exchange:
New York Stock Exchange